checkAd

    EQS-News  117  0 Kommentare SHOP APOTHEKE EUROPE: STRONG OPERATIONAL PERFORMANCE, GROWING FAST AND IMPROVING THE BOTTOM LINE. - Seite 2

    CFO, Jasper Eenhorst, adds: “We balanced growth, cost savings, and the bottom line. While we successfully continued to grow fast, we achieved a notable quarter over quarter increase in profitability. We now expect a positive adjusted EBITDA for the total group in Q3.”

    At the start of the year, the Group provided guidance for 15% to 25% sales growth for the ongoing non-Rx business for full-year 2022, and has constantly delivered on this guidance. In Q3, non-Rx sales expanded by 22% year over year, with 21% growth in the DACH segment (Germany, Austria and Switzerland), and 25% in the International segment (Belgium, the Netherlands, France and Italy).

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Redcare Pharmacy N.V.!
    Long
    96,41€
    Basispreis
    1,43
    Ask
    × 7,60
    Hebel
    Short
    123,00€
    Basispreis
    1,44
    Ask
    × 7,58
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    Sales in DACH increased from EUR 189 million in Q3 2021 to EUR 224 million in Q3 2022, with Rx sales in Germany in Q3 at EUR 33 million (Q3 2021: EUR 32M). In International, sales rose by 25% from EUR 48 million last year to EUR 61M. Total Group sales increased by 20% to EUR 285 million in Q3 (Q3 2021: EUR 238M). Year-to-date (9M), total sales grew 14% to EUR 877 million (9M 2021: EUR 772M).

    On 1 September, the roll-out of e-prescriptions (eRx) started in Westfalen-Lippe. Following the test phase that ended successfully this summer with all criteria met by mid-July, the roll-out is a significant next step in the countrywide adoption of electronic prescriptions in Germany. In Q1, the average number of daily electronic prescriptions across Germany was around 70, in Q2 around 400, and in the last week of September more than 6,000.

    The Management Board of SHOP APOTHEKE EUROPE reiterates its guidance for the ongoing business to grow non-Rx sales by 15% to 25% in the full year 2022, and to achieve an adjusted EBITDA margin in the range of -1.5% to 1.5%.

    All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE N.V. will release the Interim Report for Q3 2022 on 31 October 2022.

     

    ABOUT SHOP APOTHEKE EUROPE.

    SHOP APOTHEKE EUROPE is one of Europe’s leading and fastest-growing online pharmacies, currently operating in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

    Headquartered in the Dutch logistics hub of Sevenum near Venlo with locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven, SHOP APOTHEKE EUROPE offers its customers a broad range of more than 100,000 original products at attractive prices: OTC, beauty and personal care products as well as prescription drugs, supplemented by high quality natural food and health products, low carb products and sports nutrition. Currently, 8.9 million active customers trust SHOP APOTHEKE EUROPE.

    Seite 2 von 3


    Diskutieren Sie über die enthaltenen Werte

    Aktuelle Themen


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News SHOP APOTHEKE EUROPE: STRONG OPERATIONAL PERFORMANCE, GROWING FAST AND IMPROVING THE BOTTOM LINE. - Seite 2 EQS-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): 9 Month figures/Preliminary Results SHOP APOTHEKE EUROPE: STRONG OPERATIONAL PERFORMANCE, GROWING FAST AND IMPROVING THE BOTTOM LINE. 05.10.2022 / 07:00 CET/CEST The issuer is solely responsible …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer